Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells

  • Park, Jae-Hyun (Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea) ;
  • Ryu, Chung Heon (Department of Biomedical Science, College of Medicine, The Catholic University of Korea) ;
  • Kim, Mi Jin (Department of Biomedical Science, College of Medicine, The Catholic University of Korea) ;
  • Jeun, Sin-Soo (Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea)
  • Received : 2014.11.19
  • Accepted : 2015.03.05
  • Published : 2015.05.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : Malignant gliomas are the most common primary tumors of the central nervous system and the prognosis of patients with gliomas is poor. The combination of interferon-bata (IFN-${\beta}$) and temozolomide (TMZ) has shown significant additive antitumor effects in human glioma xenograft models. Considering that the poor survival of patients with human malignant gliomas relates partly to the inability to deliver therapeutic agents to the tumor, the tropism of human bone marrow-derived mesenchymal stem cells (MSC) for malignant gliomas can be exploited to therapeutic advantages. We investigated the combination effects of TMZ and MSCs that secrete IFN-${\beta}$ on gliomas. Methods : We engineered human MSCs to secret mouse IFN-${\beta}$ (MSC-IFN-${\beta}$) via adenoviral transduction and confirmed their secretory capacity using enzyme-linked immunosorbent assays. In vitro and in vivo experiments were performed to determine the effects of the combined TMZ and MSC-IFN-${\beta}$ treatment. Results : In vitro, the combination of MSC-IFN-${\beta}$ and TMZ showed significantly enhanced antitumor effects in GL26 mouse glioma cells. In vivo, the combined MSC-IFN-${\beta}$ and TMZ therapy significantly reduced the tumor size and improved the survival rates compared to each treatment alone. Conclusion : These results suggest that MSCs can be used as an effective delivery vehicle so that the combination of MSC-IFN-${\beta}$ and TMZ could be considered as a new option for the treatment of malignant gliomas.

Keywords

References

  1. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB : Evaluation of a tetrazolium-based semiautomated colorimetric assay : assessment of chemosensitivity testing. Cancer Res 47 : 936-942, 1987
  2. Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM, et al. : Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31 : 146-155, 2013 https://doi.org/10.1002/stem.1247
  3. Jin HT, Youn JI, Kim HJ, Lee JB, Ha SJ, Koh JS, et al. : Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther 16 : 328-338, 2005 https://doi.org/10.1089/hum.2005.16.328
  4. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, et al. : Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 68 : 9614-9623, 2008 https://doi.org/10.1158/0008-5472.CAN-08-0451
  5. Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J, et al. : Improving prognosis of glioblastoma in the 21st century : who has benefited most? Cancer 118 : 4228-4234, 2012 https://doi.org/10.1002/cncr.26685
  6. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. : Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65 : 3307-3318, 2005 https://doi.org/10.1158/0008-5472.CAN-04-1874
  7. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, et al. : IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65 : 7573-7579, 2005 https://doi.org/10.1158/0008-5472.CAN-05-0036
  8. Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, et al. : A combination of IFN-beta and temozolomide in human glioma xenograft models : implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 61 : 653-659, 2008 https://doi.org/10.1007/s00280-007-0520-x
  9. Ryu CH, Yoon WS, Park KY, Kim SM, Lim JY, Woo JS, et al. : Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol 2012 : 987495, 2012
  10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005 https://doi.org/10.1056/NEJMoa043330
  11. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Yoshimine T, Hashimoto N, et al. : A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol 38 : 715-718, 2008 https://doi.org/10.1093/jjco/hyn095

Cited by

  1. Stem cell-based therapies for tumors in the brain: are we there yet? vol.18, pp.8, 2015, https://doi.org/10.1093/neuonc/now096
  2. Harnessing mesenchymal stem cell homing as an anticancer therapy vol.16, pp.9, 2015, https://doi.org/10.1080/14712598.2016.1196179
  3. Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery vol.139, pp.2, 2018, https://doi.org/10.1007/s11060-018-2889-2
  4. The impact of Mesenchymal Stem Cells and their secretome as a treatment for gliomas vol.155, pp.None, 2018, https://doi.org/10.1016/j.biochi.2018.07.008
  5. Theranostic Nanomedicine for Malignant Gliomas vol.7, pp.None, 2015, https://doi.org/10.3389/fbioe.2019.00325
  6. Current promising treatment strategy for glioblastoma multiform: A review vol.13, pp.2, 2015, https://doi.org/10.4081/oncol.2019.417
  7. p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro vol.53, pp.3, 2015, https://doi.org/10.1590/1414-431x20198876
  8. Nanoparticles for Stem Cell Therapy Bioengineering in Glioma vol.8, pp.None, 2015, https://doi.org/10.3389/fbioe.2020.558375
  9. Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance vol.21, pp.16, 2020, https://doi.org/10.3390/ijms21165631
  10. Research Progress in Bioinspired Drug Delivery Systems vol.17, pp.9, 2020, https://doi.org/10.1080/17425247.2020.1783235
  11. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells vol.11, pp.3, 2015, https://doi.org/10.7150/thno.50150
  12. Mesenchymal stem cells, exosomes and exosome-mimics as smart drug carriers for targeted cancer therapy vol.209, pp.p1, 2015, https://doi.org/10.1016/j.colsurfb.2021.112163